Citizens Jmp upgraded shares of Astria Therapeutics (NASDAQ:ATXS - Free Report) to a strong-buy rating in a research report sent to investors on Friday,Zacks.com reports.
Other equities analysts have also issued reports about the company. JMP Securities assumed coverage on Astria Therapeutics in a research note on Friday. They issued an "outperform" rating and a $26.00 target price on the stock. Oppenheimer increased their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a report on Thursday, November 14th. Finally, HC Wainwright reiterated a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a report on Thursday, January 23rd. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $25.67.
Read Our Latest Report on ATXS
Astria Therapeutics Trading Up 0.8 %
Shares of NASDAQ:ATXS traded up $0.06 during mid-day trading on Friday, hitting $7.49. 159,271 shares of the company traded hands, compared to its average volume of 298,497. The stock has a 50-day moving average price of $8.88 and a two-hundred day moving average price of $10.40. Astria Therapeutics has a 12-month low of $7.16 and a 12-month high of $16.90. The stock has a market cap of $422.66 million, a P/E ratio of -3.59 and a beta of 0.68.
Institutional Trading of Astria Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of ATXS. Quest Partners LLC boosted its stake in shares of Astria Therapeutics by 180.8% in the 3rd quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company's stock worth $99,000 after buying an additional 5,798 shares during the last quarter. New York State Common Retirement Fund lifted its position in Astria Therapeutics by 67.0% during the fourth quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company's stock valued at $96,000 after purchasing an additional 4,300 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Astria Therapeutics during the fourth quarter valued at $107,000. PDT Partners LLC purchased a new position in Astria Therapeutics during the third quarter valued at $140,000. Finally, SG Americas Securities LLC purchased a new position in Astria Therapeutics during the third quarter valued at $155,000. Institutional investors own 98.98% of the company's stock.
About Astria Therapeutics
(
Get Free Report)
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
Featured Articles
Before you consider Astria Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astria Therapeutics wasn't on the list.
While Astria Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
